论文信息 - A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). - 字舞流文

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak | D. Siegel | P. Moreau | G. Mihaylov | T. Masszi | A. Palumbo | V. Rajkumar | J. Matous | K. Pendergrass | A. Dimopoulos | R. Bryce | J. Gandhi | K. Halka | S. Goranov | H. Bumbea | A. O. Rocafiguera | A. Lupu | G. Fonseca | A. Stewart | A. Stewart